Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Corporate & Fiscal
Pharmaceutical Events & Conferences
Terms & Conditions
Where are cancer-treating drugs heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions.
This study investigates leading drugs to treat human cancers. It lets you assess potential sales trends at world market, therapeutic submarket, product and national level to 2022.
How will 25 leading products - including Avastin, Rituxan, Herceptin and Glivec/Gleevec - perform from 2012? See potential revenues and other information. The study also assesses eight recently approved drugs.
Our investigation gives you business research and analysis with sales forecasts. You also see forecasting of five submarkets to 2022, finding potential revenues:
• Traditional antineoplastic agents
• Novel antineoplastic agents
• Hormone therapies
• Other agents.
Find coverage of oncology R&D too, assessing trends and outlooks there.
What does the future hold? The pharma industry has great potential for improving products and increasing revenues from cancer treatments. R&D pipelines in oncology are strong.
There are many promising developments in biopharma, including antibody-drug conjugates and bispecific monoclonal antibodies. The therapeutic and commercial importance of anti-cancer agents will increase from 2012 to 2022, our analysis finds.
What about leading companies? Our work discusses Roche, Novartis, AstraZeneca, Eli Lilly, Celgene and other pharmaceutical companies, evaluating prospects of the industry and market.
Commercial opportunities for cancer treatment remain, with high revenues likely from many drugs - small-molecule products and biological agents (biologicals) - to 2022.
You can investigate the future of cancer treatment now, discovering potential revenues and other trends. Our report shows and explains.
Revenue forecasts, market shares, developmental trends and discussions
In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussion of R&D activities. You receive 146 tables and charts and three research interviews.
Nine ways Leading Anti-Cancer Drugs and Associated Market 2012-2022 helps you
In particular, the study gives you the following knowledge on the topic:
• Find potential revenues to 2022 for the world market and submarkets
• Discover revenue forecasts to 2022 for 26 prominent drugs
• View prospects for emerging products, seeing their potential
• See market forecasting to 2022 for the US, Japan, the UK, Germany, France, Spain, Italy (EU5), Brazil, Russia, India and China (BRIC)
• Assess leading companies, discovering activities and outlooks
• Review R&D for a range of applications, seeing pipeline trends
• Investigate competition and opportunities influencing sales
• Find out what will stimulate and restrain the industry and market
• View opinions from our survey, receiving detailed interviews.
There, you find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains.
We keep you informed about commercial trends and prospects, helping you to stay ahead.
Gain business research and analysis now for cancer treatments
Our study is for everybody needing industry and market analyses for anti-cancer drugs. You find data, trends and answers there. Please order that report now.
AB Sciences USA
Baylor College of Medicine
Bioniche Life Sciences
Bristol-Myers Squibb (BMS)
Dan L. Duncan Cancer Center
Dr. Reddy's Laboratories
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
International Cancer Genome Consortium
Johnson & Johnson (J&J)
Lester and Sue Smith Breast Center, Baylor College of Medicine
Merck & Co.
National Health Service (UK)
National Institute for Health and Clinical Excellence (NICE, UK)
Pharmaceutical Research and Manufacturers of America (PhRMA)
RBC Capital Markets
Taiho Pharma USA
Teva Pharmaceutical Industries
World Health Organization (WHO)